Targeting tumor angiogenesis with histone deacetylase inhibitors

The hydroxamic acid derivative LBH589

Zheng (David) Qian, Yukihiko Kato, Shabana Shabbeer, Yongfeng Wei, Hendrik M W Verheul, Brenda Salumbides, Tolib Sanni, Peter Atadja, Roberto Pili

Research output: Contribution to journalArticle

221 Citations (Scopus)

Abstract

Purpose: Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone deacetylase (HDAC) inhibitors have been shown to have activity against various tumor cell types by inhibiting proliferation and inducing apoptosis both in vitro and in vivo. HDAC inhibitors have also been reported to inhibit angiogenesis. The goal of this study was to characterize the antiangiogenic and antitumor activity of a recently developed HDAC inhibitor, the hydroxamic derivative LBH 589. Materials and Methods: To evaluate the antiangiogenesis activity of LBH589, we did cell cycle analysis, cell proliferation, tube formation, invasion assays in vitro, and Matrigel plug assay in vivo. To determine the antitumor activity of LBH 589, we established human prostate carcinoma cell PC-3 xenografts in vivo. To evaluate the effect of LBH589 on endothelial signaling pathways, gene expression, and protein acetylation, we did Western blots and reverse transcription-PCR in human umbilical vein endothelial cells (HUVEC). Immunohistochemical analysis was done to evaluate new blood vessel formation in vivo. Results: LBH589 induced acetylation of histone H3 and α-tubulin protein in HUVECs. Histone and nonhistone protein acetylation correlated with induction of G2-M cell cycle arrest, inhibition of HUVEC proliferation, and viability. Noncytotoxic concentrations of LBH589 inhibited endothelial tube formation, Matrigel invasion, AKT, extracellular signal-regulated kinase 1/2 phosphorylation, and chemokine receptor CXCR4 expression. In vivo dosing of mice with LBH589 (10 mg/kg/d) reduced angiogenesis and PC-3 tumor growth. Conclusion: This study provides evidence that LBH589 induces a wide range of effects on endothelial cells that lead to inhibition of tumor angiogenesis. These results support the role of HDAC inhibitors as a therapeutic strategy to target both the tumor and endothelial compartment and warrant the clinical development of these agents in combination with angiogenesis inhibitors.

Original languageEnglish (US)
Pages (from-to)634-642
Number of pages9
JournalClinical Cancer Research
Volume12
Issue number2
DOIs
StatePublished - Jan 15 2006
Externally publishedYes

Fingerprint

Hydroxamic Acids
Histone Deacetylase Inhibitors
Neoplasms
Acetylation
Human Umbilical Vein Endothelial Cells
Cell Proliferation
Histones
G2 Phase Cell Cycle Checkpoints
Proteins
Angiogenesis Inhibitors
Mitogen-Activated Protein Kinase 3
panobinostat
Chemokine Receptors
Mitogen-Activated Protein Kinase 1
Tubulin
Heterografts
Reverse Transcription
Blood Vessels
Prostate
Cell Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeting tumor angiogenesis with histone deacetylase inhibitors : The hydroxamic acid derivative LBH589. / Qian, Zheng (David); Kato, Yukihiko; Shabbeer, Shabana; Wei, Yongfeng; Verheul, Hendrik M W; Salumbides, Brenda; Sanni, Tolib; Atadja, Peter; Pili, Roberto.

In: Clinical Cancer Research, Vol. 12, No. 2, 15.01.2006, p. 634-642.

Research output: Contribution to journalArticle

Qian, ZD, Kato, Y, Shabbeer, S, Wei, Y, Verheul, HMW, Salumbides, B, Sanni, T, Atadja, P & Pili, R 2006, 'Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589', Clinical Cancer Research, vol. 12, no. 2, pp. 634-642. https://doi.org/10.1158/1078-0432.CCR-05-1132
Qian, Zheng (David) ; Kato, Yukihiko ; Shabbeer, Shabana ; Wei, Yongfeng ; Verheul, Hendrik M W ; Salumbides, Brenda ; Sanni, Tolib ; Atadja, Peter ; Pili, Roberto. / Targeting tumor angiogenesis with histone deacetylase inhibitors : The hydroxamic acid derivative LBH589. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 2. pp. 634-642.
@article{40e78d6fdcd44454985b973616b010c8,
title = "Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589",
abstract = "Purpose: Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone deacetylase (HDAC) inhibitors have been shown to have activity against various tumor cell types by inhibiting proliferation and inducing apoptosis both in vitro and in vivo. HDAC inhibitors have also been reported to inhibit angiogenesis. The goal of this study was to characterize the antiangiogenic and antitumor activity of a recently developed HDAC inhibitor, the hydroxamic derivative LBH 589. Materials and Methods: To evaluate the antiangiogenesis activity of LBH589, we did cell cycle analysis, cell proliferation, tube formation, invasion assays in vitro, and Matrigel plug assay in vivo. To determine the antitumor activity of LBH 589, we established human prostate carcinoma cell PC-3 xenografts in vivo. To evaluate the effect of LBH589 on endothelial signaling pathways, gene expression, and protein acetylation, we did Western blots and reverse transcription-PCR in human umbilical vein endothelial cells (HUVEC). Immunohistochemical analysis was done to evaluate new blood vessel formation in vivo. Results: LBH589 induced acetylation of histone H3 and α-tubulin protein in HUVECs. Histone and nonhistone protein acetylation correlated with induction of G2-M cell cycle arrest, inhibition of HUVEC proliferation, and viability. Noncytotoxic concentrations of LBH589 inhibited endothelial tube formation, Matrigel invasion, AKT, extracellular signal-regulated kinase 1/2 phosphorylation, and chemokine receptor CXCR4 expression. In vivo dosing of mice with LBH589 (10 mg/kg/d) reduced angiogenesis and PC-3 tumor growth. Conclusion: This study provides evidence that LBH589 induces a wide range of effects on endothelial cells that lead to inhibition of tumor angiogenesis. These results support the role of HDAC inhibitors as a therapeutic strategy to target both the tumor and endothelial compartment and warrant the clinical development of these agents in combination with angiogenesis inhibitors.",
author = "Qian, {Zheng (David)} and Yukihiko Kato and Shabana Shabbeer and Yongfeng Wei and Verheul, {Hendrik M W} and Brenda Salumbides and Tolib Sanni and Peter Atadja and Roberto Pili",
year = "2006",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-05-1132",
language = "English (US)",
volume = "12",
pages = "634--642",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Targeting tumor angiogenesis with histone deacetylase inhibitors

T2 - The hydroxamic acid derivative LBH589

AU - Qian, Zheng (David)

AU - Kato, Yukihiko

AU - Shabbeer, Shabana

AU - Wei, Yongfeng

AU - Verheul, Hendrik M W

AU - Salumbides, Brenda

AU - Sanni, Tolib

AU - Atadja, Peter

AU - Pili, Roberto

PY - 2006/1/15

Y1 - 2006/1/15

N2 - Purpose: Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone deacetylase (HDAC) inhibitors have been shown to have activity against various tumor cell types by inhibiting proliferation and inducing apoptosis both in vitro and in vivo. HDAC inhibitors have also been reported to inhibit angiogenesis. The goal of this study was to characterize the antiangiogenic and antitumor activity of a recently developed HDAC inhibitor, the hydroxamic derivative LBH 589. Materials and Methods: To evaluate the antiangiogenesis activity of LBH589, we did cell cycle analysis, cell proliferation, tube formation, invasion assays in vitro, and Matrigel plug assay in vivo. To determine the antitumor activity of LBH 589, we established human prostate carcinoma cell PC-3 xenografts in vivo. To evaluate the effect of LBH589 on endothelial signaling pathways, gene expression, and protein acetylation, we did Western blots and reverse transcription-PCR in human umbilical vein endothelial cells (HUVEC). Immunohistochemical analysis was done to evaluate new blood vessel formation in vivo. Results: LBH589 induced acetylation of histone H3 and α-tubulin protein in HUVECs. Histone and nonhistone protein acetylation correlated with induction of G2-M cell cycle arrest, inhibition of HUVEC proliferation, and viability. Noncytotoxic concentrations of LBH589 inhibited endothelial tube formation, Matrigel invasion, AKT, extracellular signal-regulated kinase 1/2 phosphorylation, and chemokine receptor CXCR4 expression. In vivo dosing of mice with LBH589 (10 mg/kg/d) reduced angiogenesis and PC-3 tumor growth. Conclusion: This study provides evidence that LBH589 induces a wide range of effects on endothelial cells that lead to inhibition of tumor angiogenesis. These results support the role of HDAC inhibitors as a therapeutic strategy to target both the tumor and endothelial compartment and warrant the clinical development of these agents in combination with angiogenesis inhibitors.

AB - Purpose: Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone deacetylase (HDAC) inhibitors have been shown to have activity against various tumor cell types by inhibiting proliferation and inducing apoptosis both in vitro and in vivo. HDAC inhibitors have also been reported to inhibit angiogenesis. The goal of this study was to characterize the antiangiogenic and antitumor activity of a recently developed HDAC inhibitor, the hydroxamic derivative LBH 589. Materials and Methods: To evaluate the antiangiogenesis activity of LBH589, we did cell cycle analysis, cell proliferation, tube formation, invasion assays in vitro, and Matrigel plug assay in vivo. To determine the antitumor activity of LBH 589, we established human prostate carcinoma cell PC-3 xenografts in vivo. To evaluate the effect of LBH589 on endothelial signaling pathways, gene expression, and protein acetylation, we did Western blots and reverse transcription-PCR in human umbilical vein endothelial cells (HUVEC). Immunohistochemical analysis was done to evaluate new blood vessel formation in vivo. Results: LBH589 induced acetylation of histone H3 and α-tubulin protein in HUVECs. Histone and nonhistone protein acetylation correlated with induction of G2-M cell cycle arrest, inhibition of HUVEC proliferation, and viability. Noncytotoxic concentrations of LBH589 inhibited endothelial tube formation, Matrigel invasion, AKT, extracellular signal-regulated kinase 1/2 phosphorylation, and chemokine receptor CXCR4 expression. In vivo dosing of mice with LBH589 (10 mg/kg/d) reduced angiogenesis and PC-3 tumor growth. Conclusion: This study provides evidence that LBH589 induces a wide range of effects on endothelial cells that lead to inhibition of tumor angiogenesis. These results support the role of HDAC inhibitors as a therapeutic strategy to target both the tumor and endothelial compartment and warrant the clinical development of these agents in combination with angiogenesis inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=31544464120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544464120&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1132

DO - 10.1158/1078-0432.CCR-05-1132

M3 - Article

VL - 12

SP - 634

EP - 642

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -